AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 180 filers reported holding AERIE PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.50 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $105,000 | +40.0% | 6,923 | -31.1% | 0.00% | – |
| Q2 2022 | $75,000 | -13.8% | 10,049 | +5.0% | 0.00% | – |
| Q1 2022 | $87,000 | -17.9% | 9,575 | -37.2% | 0.00% | – |
| Q4 2021 | $106,000 | +211.8% | 15,255 | +413.8% | 0.00% | – |
| Q3 2021 | $34,000 | +70.0% | 2,969 | +134.5% | 0.00% | – |
| Q2 2021 | $20,000 | -67.2% | 1,266 | -63.4% | 0.00% | – |
| Q1 2021 | $61,000 | +84.8% | 3,461 | +45.2% | 0.00% | – |
| Q4 2020 | $33,000 | +22.2% | 2,384 | +2.4% | 0.00% | – |
| Q3 2020 | $27,000 | -25.0% | 2,327 | -5.5% | 0.00% | – |
| Q2 2020 | $36,000 | -16.3% | 2,462 | -22.1% | 0.00% | – |
| Q1 2020 | $43,000 | -78.3% | 3,160 | -61.5% | 0.00% | – |
| Q4 2019 | $198,000 | +40.4% | 8,200 | +11.7% | 0.00% | – |
| Q3 2019 | $141,000 | -89.9% | 7,339 | -84.5% | 0.00% | – |
| Q2 2019 | $1,398,000 | +68.8% | 47,327 | +171.6% | 0.00% | – |
| Q1 2019 | $828,000 | +24.9% | 17,426 | -5.1% | 0.00% | – |
| Q4 2018 | $663,000 | -46.1% | 18,363 | -8.2% | 0.00% | -100.0% |
| Q3 2018 | $1,231,000 | -34.7% | 19,999 | -28.4% | 0.00% | 0.0% |
| Q2 2018 | $1,886,000 | +5.7% | 27,927 | -15.1% | 0.00% | 0.0% |
| Q1 2018 | $1,784,000 | -1.7% | 32,875 | +8.3% | 0.00% | 0.0% |
| Q4 2017 | $1,815,000 | -6.2% | 30,364 | -23.7% | 0.00% | 0.0% |
| Q3 2017 | $1,935,000 | -52.5% | 39,819 | -48.6% | 0.00% | -50.0% |
| Q2 2017 | $4,071,000 | +0.8% | 77,462 | -13.0% | 0.00% | 0.0% |
| Q1 2017 | $4,040,000 | +12.1% | 89,083 | -6.5% | 0.00% | 0.0% |
| Q4 2016 | $3,605,000 | +3.3% | 95,259 | +3.0% | 0.00% | 0.0% |
| Q3 2016 | $3,489,000 | +99.4% | 92,442 | -7.0% | 0.00% | +100.0% |
| Q2 2016 | $1,750,000 | +40.3% | 99,451 | -3.0% | 0.00% | 0.0% |
| Q1 2016 | $1,247,000 | -46.7% | 102,553 | +6.8% | 0.00% | -50.0% |
| Q4 2015 | $2,339,000 | +47.9% | 96,067 | +7.8% | 0.00% | +100.0% |
| Q3 2015 | $1,581,000 | -2.4% | 89,112 | -2.9% | 0.00% | 0.0% |
| Q2 2015 | $1,620,000 | -49.9% | 91,796 | -11.0% | 0.00% | -50.0% |
| Q1 2015 | $3,231,000 | +45.1% | 103,095 | +35.1% | 0.00% | +100.0% |
| Q4 2014 | $2,227,000 | +71.8% | 76,308 | +21.8% | 0.00% | 0.0% |
| Q3 2014 | $1,296,000 | +747.1% | 62,656 | +914.7% | 0.00% | – |
| Q2 2014 | $153,000 | -83.1% | 6,175 | -85.5% | 0.00% | -100.0% |
| Q1 2014 | $905,000 | +18000.0% | 42,727 | +15437.1% | 0.00% | – |
| Q4 2013 | $5,000 | – | 275 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
| LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
| DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
| DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
| Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
| PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
| Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |